Holt J A, Waggoner S E, Lee E Y, Hubby M M, Hamilton T C
Gynecol Oncol. 1987 Jul;27(3):282-93. doi: 10.1016/0090-8258(87)90248-4.
The human ovarian carcinoma cell line NIH-OVCAR-3 grown in immunodeficient mice has been reported to be sensitive to estrogen medications and to express progestin receptor. To assess the effects of sex steroids on CA 125 production and survival times in these mice, we administered Tamoxifen, estrogen, and progestin. During the first 28 days after inoculation of mice with 2.3 million tumor cells ip, serum CA 125 rose exponentially, reaching 4308 +/- 776 and 3905 +/- 1013 units/ml (mean +/- SEM, P greater than 0.1) in placebo- and Tamoxifen-treated mice, respectively; median survival times were 41 and 39 days, respectively (P greater than 0.1). Uninoculated mice had nondetectable CA 125, and all outlived the inoculated mice. In tumor-inoculated mice, serum CA 125 levels and survival were similar when estrogen or progestin was injected alone and when both were given in combination. We detected no significant differences in production of CA 125 in vitro by tumor cells harvested from ascites fluid when the mice were treated with placebo, estrogen, or progestin. We conclude that, for our model, serial measurements of serum CA 125 provide excellent estimates of the relationship between tumor burden and survival, and that CA 125 production appears unaffected by estrogen, progestin, or Tamoxifen.
据报道，在免疫缺陷小鼠体内生长的人卵巢癌细胞系NIH-OVCAR-3对雌激素药物敏感并表达孕激素受体。为了评估性类固醇对这些小鼠CA 125产生及生存时间的影响，我们给予了他莫昔芬、雌激素和孕激素。在给小鼠腹腔注射230万个肿瘤细胞后的头28天内，血清CA 125呈指数上升，在接受安慰剂和他莫昔芬治疗的小鼠中，分别达到4308±776和3905±1013单位/毫升（平均值±标准误，P>0.1）；中位生存时间分别为41天和39天（P>0.1）。未接种的小鼠CA 125检测不到，且全部比接种小鼠存活时间长。在接种肿瘤的小鼠中，单独注射雌激素或孕激素以及两者联合注射时，血清CA 125水平和生存情况相似。当小鼠接受安慰剂、雌激素或孕激素治疗时，我们从腹水采集的肿瘤细胞在体外CA 125的产生方面未检测到显著差异。我们得出结论，对于我们的模型，血清CA 125的系列测量能很好地估计肿瘤负荷与生存之间的关系，并且CA 125的产生似乎不受雌激素、孕激素或他莫昔芬的影响。
